Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds

Next Previous
X
Search
Trial Profile

A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AGLE 103 (Primary)
  • Indications Epidermolysis bullosa dystrophica
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aegle Therapeutics

    • Most Recent Events

    • 14 Aug 2024 According to Aegle Therapeutics media release, Status changed from not yet recruiting to recruiting.
    • 14 Aug 2024 According to Aegle Therapeutics media release, the company announced that the first patient has been dosed in this study.
    • 11 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 1 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top